Dagliflozin tablets belong to a new type of hypoglycemic drugs, itself belongs to the sodium-glucose co-transporter protein 2 inhibitor, can inhibit glucose reabsorption, to achieve the purpose of controlling blood sugar. Dagliflozin tablets are suitable for blood glucose control in patients with type 2 diabetes on the basis of exercise and dietary control of blood glucose, and can be used alone. Hypotension, ketoacidosis, hypoglycemia, kidney damage, urinary tract infections, elevated LDL, and bladder cancer may occur during the administration of Dagliflozin Tablets. Dagliflozin Tablets are contraindicated in children, during pregnancy and breastfeeding, in people with obvious kidney damage, ketoacidosis, in people with urinary tract inflammation and family history of bladder cancer, and in people who are allergic to the product. Dagliflozin tablets need to follow the doctor’s instructions for medication; during the use of the drug, closely monitor the kidney function, monitor the status of urinary tract infections; avoid drinking alcohol during the use of the drug. This drug needs to be standardized under the guidance of a doctor, avoid private use of the drug, so as not to lead to adverse reactions.